Given the rapid global aging trend, the prevalence of cognitive impairment is escalating rapidly, posing an urgent public health concern.1 The primary causes of cognitive impairment are Alzheimer’s disease (AD) and vascular cognitive impairment (VCI), respectively.2,3 According to the diagnostic criteria, AD is a cognitive disorder due to the deposition of core pathological proteins such as amyloid beta () and phosphorylated tau proteins, whereas VCI is a cognitive disorder due to cerebrovascular disease.4,5 The clinical symptoms of AD and VCI are similar, including cognition disorders and mental symptoms, which are easily confused in clinics.2,3 Neuropsychological examination reveals that AD cognitive deficits are more frequently characterized by impairments in amnestic and parietal functions, whereas VCI is more often associated with attentional and executive dysfunction.6 Pathologically, AD is pathologically characterized by the presence of plaques, phosphorylated tau, neurofibrillary tangles, and cerebrovascular amyloidosis, whereas VCI is pathologically characterized as ischemic, hypoperfusion, and hemorrhagic damage.4,7 Therefore, it is crucial to distinguish between AD and VCI to guide treatment and evaluate the prognosis of cognitive impairment for more appropriate treatment. Currently, neuroimaging tests are used to identify AD and VCI, but the method is time-consuming and expensive.8 The eye is considered as the window of the brain, and ocular examination is an objective, quick, and low-cost alternative. As a result, ocular examination has recently become a research focus for detecting cognitive impairment.1,9 – 13